Monocarboxylate Transporter Dynamics in Cancer Metabolism

Monocarboxylate transporters (MCTs) mediate the proton‐coupled movement of lactic acid and other monocarboxylates across the plasma membrane, playing a central role in the metabolic reprogramming of cancer cells. Tumours often rely on aerobic glycolysis, producing high levels of lactate that are exported by MCT4 from hypoxic, highly glycolytic cells and imported by MCT1 into more oxidative cells. This lactate shuttle creates a metabolic symbiosis that supports energy production, maintains redox balance and acidifies the microenvironment, thereby promoting invasion, angiogenesis and immune modulation. Expression of MCTs is regulated at multiple levels: transcriptionally by factors such as HIF-1α under low-oxygen conditions; post-translationally by ubiquitination and chaperone interactions; and by non-coding RNAs that fine-tune transporter abundance. Crosstalk with stromal cells, including fibroblasts and adipocytes, further diversifies intratumoral metabolic niches. Pharmacological inhibitors, genetic silencing and antibody blockade of MCTs have demonstrated efficacy in impairing tumour growth, metastasis and resistance to chemotherapeutics, underscoring their promise as biomarkers and therapeutic targets.

Research from Nature Portfolio

Recent studies have illuminated the interplay between transporter regulation and tumour–stroma communication. One investigation revealed that breast cancer cells expressing MCT2 co-opt β-hydroxybutyrate released by mammary adipocytes to induce global histone acetylation and drive transcription of oncogenic programmes, thereby enhancing tumourigenesis in vitro and in orthotopic models. Another report identified a tumour-suppressive microRNA whose downregulation in triple-negative breast cancer leads to MCT1 overexpression. Restoration of this microRNA disrupted lactate and glucose fluxes, increased oxidative stress under nutrient deprivation and impaired proliferation and migration, offering a novel avenue to counteract metabolic adaptation in aggressive breast tumours.

Monocarboxylate Transporter Dynamics in Cancer Metabolism publication trend

The graph below shows the total number of articles in monocarboxylate transporter dynamics in cancer metabolism across all publications each year (not limited to Nature Index journals).

Technical terms

Monocarboxylate transporter (MCT): A membrane protein that co-transports protons and monocarboxylates (e.g. lactate, pyruvate) to regulate cellular metabolism and pH.

Lactate shuttle: The transfer of lactate between cells or cellular compartments, linking glycolytic and oxidative metabolic phenotypes.

Hypoxia: A state of reduced oxygen availability that stabilises HIF-1α, triggering transcriptional programmes for metabolic adaptation.

MicroRNA (miRNA): A short non-coding RNA that binds target mRNAs to repress translation or induce degradation, modulating protein expression.

E3 ubiquitin ligase: An enzyme that catalyses the attachment of ubiquitin to specific protein substrates, controlling their localisation, activity or stability.

References

1. Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments. Disease Models & Mechanisms (2011).
2. The Plasma Membrane Lactate Transporter MCT4, but Not MCT1, Is Up-regulated by Hypoxia through a HIF-1α-dependent Mechanism*. Journal of Biological Chemistry (2006).
3. Adipocytes promote malignant growth of breast tumours with monocarboxylate transporter 2 expression via β-hydroxybutyrate. Nature Communications (2017).
4. Loss of function of miR-342-3p results in MCT1 over-expression and contributes to oncogenic metabolic reprogramming in triple negative breast cancer. Scientific Reports (2018).
5. Deciphering metabolic heterogeneity in retinoblastoma unravels the role of monocarboxylate transporter 1 in tumor progression. Biomarker Research (2024).
6. SYVN1-mediated ubiquitylation directs localization of MCT4 in the plasma membrane to promote the progression of lung adenocarcinoma. Cell Death & Disease (2023).
7. Monocarboxylate Transporter-1 (MCT1)-Mediated Lactate Uptake Protects Pancreatic Adenocarcinoma Cells from Oxidative Stress during Glutamine Scarcity Thereby Promoting Resistance against Inhibitors of Glutamine Metabolism. Antioxidants (2023).